Jeetinder Singh Mahal

CIK: 0001882877

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (25.0%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

JSPR

Jasper Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

JSPR
Jasper Therapeutics, Inc.
Feb 6, 2026
Award(A)
Stock Option (right to buy)
Direct
500K shares-
JSPR
Jasper Therapeutics, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
90K shares-
JSPR
Jasper Therapeutics, Inc.
Jun 4, 2025
Award(A)
Stock Option (right to buy)
Direct
90K shares-
JSPR
Jasper Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (right to buy)
Direct
50K shares-
JSPR
Jasper Therapeutics, Inc.
Dec 12, 2024
Exercise(M)
Direct
900 shares at avg. $7.10$6K
JSPR
Jasper Therapeutics, Inc.
Dec 12, 2024
Sale(S)
Direct
900 shares at avg. $22.11$20K
JSPR
Jasper Therapeutics, Inc.
Sep 12, 2024
Exercise(M)
Direct
900 shares at avg. $7.10$6K
JSPR
Jasper Therapeutics, Inc.
Sep 12, 2024
Sale(S)
Direct
900 shares at avg. $21.23$19K

		Type	Shares	Price		Ownership
Feb 6, 2026	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	500,000	-	-	Direct
Jan 2, 2026	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	90,000	-	-	Direct
Jun 4, 2025	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	90,000	-	-	Direct
Feb 13, 2025	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	50,000	-	-	Direct
Dec 12, 2024	JSPR Jasper Therapeutics, Inc.	Exercise(M)	900	$7.10	$6,390	Direct
Dec 12, 2024	JSPR Jasper Therapeutics, Inc.	Sale(S)	900	$22.11	$19,899	Direct
Sep 12, 2024	JSPR Jasper Therapeutics, Inc.	Exercise(M)	900	$7.10	$6,390	Direct
Sep 12, 2024	JSPR Jasper Therapeutics, Inc.	Sale(S)	900	$21.23	$19,104	Direct

1-8 of 8 transactions

About Mahal Jeetinder Singh

Mahal Jeetinder Singh (SEC CIK 0001882877) files insider reports with the SEC as CEO and President of Jasper Therapeutics, Inc. (JSPR).

Signal8 holds 6 ownership filings by Mahal Jeetinder Singh, all Form 4s, filed between Sep 12, 2024 and Feb 10, 2026. Those filings report 8 transactions, from Sep 12, 2024 to Feb 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mahal Jeetinder Singh's filings is in REDWOOD CITY, CA.

Recent filings by Mahal Jeetinder Singh

Feb 6, 2026: Grant or award of JSPR derivative securities (Form 4, code A).
Jan 2, 2026: Grant or award of JSPR derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of JSPR derivative securities (Form 4, code A).
Feb 13, 2025: Grant or award of JSPR derivative securities (Form 4, code A).
Dec 12, 2024: Option exercise of JSPR shares (Form 4, code M).

Other insiders filing for Jasper Therapeutics, Inc. (JSPR)

WIGGANS THOMAS G, Director
Lucas Svetlana, Director
Crutcher Patrick J, Director
EMSTER KURT VON, Director
Shizuru Judith Anne, Director
Keenan Greg, Chief Medical Officer

How to read Form 4 transaction codes